{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"ABBV400"},{"type":"CodeName","name":"ABBV 400"},{"type":"CodeName","name":"ABBV-400"},{"type":"Synonym","name":"c-Met ADC ABBV-400"},{"type":"Synonym","name":"ADC ABBV-400"},{"type":"Synonym","name":"anti-c-Met antibody-drug conjugate ABBV-400"},{"type":"CASRegistryName","name":"2850366-99-1"},{"type":"Synonym","name":"anti-c-Met ADC ABBV-400"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an undisclosed topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the topoisomerase inhibitor is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.","text":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an undisclosed topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the topoisomerase inhibitor is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis."},"drugInfoSummaryLink":null,"nciConceptId":"C184368","nciConceptName":"Telisotuzumab Adizutecan","termId":806804,"name":"telisotuzumab adizutecan","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"telisotuzumab-adizutecan"}],"links":null}